| | SAN DIEGO, Calif., /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in two upcoming investor conferences: - Evercore ISI HealthCONx Conference – Presenting on Wednesday, November 28, at 4:15PM EST in Boston
- Citi Global Healthcare Conference – Hosting investor meetings on Wednesday, December 5 and Thursday, December 6, in New York City
A live audio webcast of the presentation will be available under the investor relations section of Arena’s website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. About Arena Pharmaceuticals
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Arena’s proprietary pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility. Etrasimod (APD334), with potential utility in a broad range of immune and inflammatory conditions, is being evaluated in later-stage clinical programs in ulcerative colitis (UC) and Crohn’s disease, as well as in programs for primary biliary cholangitis (PBC) and atopic dermatitis. Ralinepag (APD811) is being evaluated in a Phase 3 program for pulmonary arterial hypertension (PAH). Arena is also evaluating olorinab (APD371) in a Phase 2 program for gastrointestinal pain. Arena continues to assess other earlier research and development stage drug candidates, including APD418 for decompensated heart failure. In addition, Arena has several partnerships including with Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries), Axovant Sciences GmbH (nelotanserin - Phase 2), Boehringer Ingelheim International GmbH (undisclosed target - preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® - marketed product). Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements may be accompanied by words such as “will,” “driven to,” “potentially,” “potential,” or words of similar meaning, or they may be identified by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include, without limitation, statements about Arena’s participation in the upcoming investor conferences and Arena’s drive, focus, goals, strategy, clinical and research and development programs, and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include that clinical and preclinical programs may not proceed at the time or in the manner expected or at all, as well as those factors disclosed in Arena’s filings with the Securities and Exchange Commission (SEC), including but not limited to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, which was filed with the SEC on November 8, 2018. These forward-looking statements represent Arena’s judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.  View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-participate-in-upcoming-investor-conferences-300753358.html
SOURCE Arena Pharmaceuticals, Inc. | |
